Mesoblast signals commercial turn as Ryoncil sales reach roughly $115m in fiscal 2026
The cell therapy company's chair told shareholders the group is prioritising selling over discovery, pointing to its paediatric transplant-complication drug as the first real test of demand.
Mesoblast is recasting itself as a commercial-stage company. Its chair told the 2026 annual general meeting that the business is moving away from a model built around research and towards one focused on execution in the market, according to the remarks reported from the meeting.
The justification is revenue from Ryoncil (remestemcel-L-rknd), approved for children with steroid-refractory acute graft-versus-host disease. The chair put net sales for fiscal 2026 at roughly US$115m. The material available does not break that figure down by quarter, customer, payer or geography, so the pace of uptake within the year is not clear.
On the pipeline, the chair said enrolment is complete in the Phase 3 trial of rexlemestrocel-L in chronic low back pain. Separately, enrolment has started in a registrational trial of Ryoncil in adults, a step that could point to a wider patient population if the study succeeds. No timelines for data or regulatory filings were given.
Shareholders were also asked to vote on the election of a director nominee. No further details on the nominee were available.
Why it matters
- About US$115m in first-full-year-scale net sales gives investors and partners an early reference point for how an approved cell therapy can sell in a narrow paediatric indication.
- The adult Ryoncil trial is the main route to a larger addressable market, but without timelines its commercial value remains unquantified.
- Finished enrolment in the low back pain Phase 3 brings the second asset nearer to a readout, though no date was disclosed.
- The strategic shift puts the focus on sales execution, where details such as pricing, reimbursement and margins were not provided.
Company's press release (SEC filing): Mesoblast Ltd ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Praxis Precision Medicines sets peak sales view above $20bn at New York Investor Day
Taysha completes TSHA-102 PPQ campaign and reports no severe treatment-related SAEs in 33 patients
